ACE2 and COVID-19: In two distinct cohorts of heart failure patients with COVID-19, men had higher plasma concentrations of ACE2 than women, hence ACE inhibitors and angiotensin receptor blockers were associated with lower plasma concentrations of ACE2, but mineralocorticoid receptor antagonists were associated with higher concentrations [98].